Life Science Investing Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 21 October
Life Science Investing SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress 21 October
Life Science Investing Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet 20 October
